Skip to main content

Table 1 Late term status after TEVG implantation in clinical trial

From: Challenges in translating vascular tissue engineering to the pediatric clinic

Patient Age at Operation (Years) Patient Status Graft Status Graft Patency Graft Related Complications
1 2 alive intact patent none
2 1 alive intact patent none
3 7 alive intact patent stenosis
4 21 alive intact patent none
5 4 alive intact patent none
6 12 alive intact patent none
7 17 alive intact patent none
8 19 dead intact patent none
9 3 alive intact patent stenosis
10 2 dead intact patent none
11 13 alive intact patent stenosis
12 2 dead intact patent none
13 2 alive intact patent thrombosis
14 2 alive intact patent none
15 2 alive intact patent none
16 2 alive intact patent none
17 24 alive intact patent none
18 1 alive intact patent stenosis
19 11 alive intact patent none
20 2 alive intact patent none
21 3 alive intact patent none
22 4 alive intact patent none
23 4 alive intact patent none
24 13 alive intact patent none
25 2 dead intact patent none
  1. Most recent follow-up at mean of 5.8 years showed no graft-related mortality and no evidence of aneurysm formation, graft rupture, or ectopic calcification. 4 out of 25 patents developed asymptomatic stenosis that was picked up on routine serial imaging and were successfully treated with angioplasty. All implanted TEVG are currently intact and patent. (Adapted from Hibino (2010) with permission from Elsevier [40]).